🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. Enasidenib Mesilate, Enasidenib Mesilate, Ivosidenib, Vidaza 25 mg/ml powder for suspension for injection

    Celgene Europe Limited

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  2. Encochleated Amphotericin B

    Matinas BioPharma Holdings

    Cryptococcal Infections

    phase 2 small molecule terminated

    1 trial

  3. Entrectinib

    Hoffmann-La Roche

    Solid Tumors

    phase 2 small molecule active

    1 trial

  4. Entrectinib

    Hoffmann-La Roche

    Breast Cancer

    phase 2 small molecule active

    1 trial

  5. Envafolimab Injection

    The First People's Hospital of Lianyungang

    Gastrointestinal Neoplasms

    phase 2 small molecule active

    1 trial

  6. Epetraborole

    AN2 Therapeutics

    Mycobacterium Abscessus Infection

    phase 2 small molecule active

    1 trial

  7. Esmolol HCl LYO Orpha 2500 mg poeder voor concentraat voor oplossing voor infusie, Milrinon Hikma 1 mg/ml oplossing voor injectie, Dobutamine-hameln 5 mg/ml i.v. infusievloeistof, oplossing voor infusie

    Disc Medicine

    Cardiogenic shock

    phase 2 small molecule active

    1 trial

  8. Etoposide 20 mg/ml Concentrate for Solution for Infusion, Sodium Chloride 0.9% Intravenous Infusion BP, Vincristine Sulfate 1 mg/ml Solution for Injection or Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Human Albumin Baxalta 50 g/l Solution for Infusion, Cyclophosphamide 1000 mg Powder for Solution for Injection or Infusion, Qarziba 4.5 mg/mL concentrate for solution for infusion, Dacarbazine Lipomed 200 mg powder for solu

    AXIM BIOTECHNOLOGIES, INC.

    Neuroblastoma

    phase 2 small molecule active

    1 trial

  9. Exenatide 3.5μg/mL solution for subcutaneous injection, Potassium canrenoate 5mg/mL solution for intravenous injection, Amodiaquine+Glibenclamide (10mg+0.1mg) /5mL oral suspension, Amodiaquine 2mg/mL solution for intravenous injection, Potassium canrenoate 25mg/5mL oral suspension

    Lacuna Pharma Pty Ltd

    Acute Ischemic Stroke

    phase 2 small molecule active

    1 trial

  10. Expanded , Activated NK cells

    Hospital Authority, Hong Kong

    Ewing Sarcoma

    phase 2 mab active

    1 trial

  11. Experimental 1 - DBS of bilateral NAc - 6 months of active stimulation -- > 6 months of sham stimulation

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Use Disorder

    phase 2 other active

    1 trial

  12. FDC Nivolumab + Relatlimab + rHuPH20 Injection, Nivolumab/Relatlimab, OPDIVO 10 mg/mL concentrate for solution for infusion., Nivolumab Subcutaneous

    Bristol-Myers Squibb Australia Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  13. FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, S241656 film-coated tablet 50mg, Erbitux 5 mg/mL solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion, S241656 film-coated tablet 25mg, Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bugvi 5 mg/ml pulbere pentru dispersie perfuzabilă, Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung,

    The George Institute

    Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations

    phase 2 small molecule active

    1 trial

  14. FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, Fluorouracil Accord 50 mg/ml Injektions-/ Infusionslösung, Fluorouracile AHCL 50 mg/ml, Soluzione per iniezione o infusione, SOTORASIB, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Fluorouracilo Accord 50 mg/ml solución inyectable o para perfusión EFG, FLUOROURACILE ACCORD 50 mg/ml, solutio

    CERO THERAPEUTICS HOLDINGS, INC.

    colorectal cancer

    phase 2 small molecule active

    1 trial

  15. FORTRANS, poudre pour solution buvable en sachet., TOXICARB, suspension buvable

    Pari Pharma GmbH

    Major patients intoxicated by functional toxicant(s), hospitalized in intensive care and intubated.

    phase 2 small molecule active

    1 trial

  16. FSD201

    Quantum Biopharma

    Mast Cell Activation Syndrome

    phase 2 small molecule terminated

    1 trial

  17. FST-100

    Takeda

    Acute Adenoviral Conjunctivitis

    phase 2 small molecule completed

    1 trial

  18. FST-100

    Takeda

    Acute Viral Conjunctivitis

    phase 2 small molecule completed

    1 trial

  19. FST-100 Ophthalmic Suspension

    Takeda

    Acute Adenoviral Conjunctivitis

    phase 2 small molecule terminated

    1 trial

  20. Faslodex 250 mg solution for injection., PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB

    Ningbo Cancer Hospital

    Metastatic breast cancer

    phase 2 small molecule active

    1 trial

  21. Fazisiran Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial

  22. Ferroquine SSR97193

    Sanofi Pasteur

    Plasmodium Falciparum Infection

    phase 2 small molecule terminated

    1 trial

  23. Fibromun, Darleukin

    Philogen S.p.A.

    Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.

    phase 2 small molecule active

    1 trial

  24. Fibromun, Darleukin

    Philogen S.p.A.

    Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources